- Home
- LBPH
as 07-26-2024 4:00pm EST
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | 810.3M | IPO Year: | 2021 |
| Target Price: | $45.38 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.60 - $40.48 | Next Earning Date: | 08-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Longboard Pharmaceuticals Inc. (LBPH)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ARENA PHARMACEUTICALS INC | LBPH | Jan 25 '24 | Sell | $24.25 | 3,978,540 | $96,479,595.00 | 0 | SEC Form 4 |
Latest Longboard Pharmaceuticals Inc. News
LBPH Breaking Stock News: Dive into LBPH Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Longboard Pharmaceuticals (LBPH) Is a Great Choice for 'Trend' Investors, Here's Why
Motley Fool
4 days ago
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
GuruFocus.com
11 days ago
Andreas Halvorsen's Strategic Acquisition in Longboard Pharmaceuticals
MT Newswires
15 days ago
Baird Adjusts Price Target on Longboard Pharmaceuticals to $60 From $36, Maintains Outperform Rating
Zacks
17 days ago
Wall Street Analysts Think Longboard Pharmaceuticals (LBPH) Could Surge 43.7%: Read This Before Placing a Bet
Zacks
17 days ago
Longboard Pharmaceuticals (LBPH) is on the Move, Here's Why the Trend Could be Sustainable
Business Wire
23 days ago
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Zacks
24 days ago
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Compare LBPH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LBPH Longboard Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.